Alexandria Real Estate Equities, Inc. (ARE)

Alexandria Real Estate Equities, Inc. is a leading specialized "urban office REIT focused on collaborative life science, agtech, and technology campuses," currently led by Executive Chairman and Founder Joel Marcus and CEO Peter Moglia. The company’s mission is to provide high-quality, mission-critical environments for the worlds most innovative companies. Alexandria holds a strategic position as the "Pioneer of the Life Science Real Estate Niche," owning and operating a massive portfolio in AAA innovation clusters like Cambridge, San Francisco, and San Diego. Alexandria Real Estate Equities, Inc. stock is a premier "Biotech Infrastructure" play, representing a company that provides the specialized lab space required for modern drug discovery.

The company’s business operations are built on its specialized "Lab-Space Core," where over 90% of its tenants are investment-grade or large-cap life science firms. In late 2025, Alexandria reported record occupancy levels in its specialized "Mega-Campus" developments, as biotech firms continued to prioritize high-tech laboratory facilities over traditional office space. The company’s future strategy involves "Mega-Cluster Dominance," with 2026 targets focused on the delivery of its $5 billion active development pipeline. For 2026, the firm is prioritizing its specialized "Alexandria LaunchLabs®" to incubate the next generation of life science startups. Its competitive moat is its "Niche Expertise and Location"—the specialized HVAC, plumbing, and safety requirements of a wet-lab are incredibly complex and expensive to build, making Alexandria’s existing campuses virtually irreplaceable assets. By December 2025, Alexandria remains a resilient and vital leader in the real estate sector, utilizing its technical superiority in lab design to support the future of human health.

ARE is listed on the New York Stock Exchange under the ticker ARE stock. It is a favorite for investors seeking exposure to the biotech revolution with the safety of a high-quality real estate backing. Financial analysts and life science experts monitor the ARE stock price as a leading indicator of biotech R&D intensity and the demand for high-tech urban infrastructure. By December 2025, Alexandria Real Estate Equities stands as a technologically superior and powerful force in the property industry, utilizing its scale to empower scientific discovery.